Dechra Pharmaceuticals Limited, a Northwich, Cheshire, UK-based supplier of a veterinary prescription drugs enterprise, acquired Invetx Inc., a Boston, MA-base firm which makes a speciality of protein-based therapeutics for animal well being, for as much as $520M.
The acquisition stays topic to antitrust approval and different customary closing situations.
Along with the Invetx pipeline, Dechra will achieve entry to the corporate’s species-specific, half-life extension platform, which extends length of drug exercise and permits longer intervals between remedy, providing higher comfort and improved compliance for veterinarians, homeowners and their pets.
Led by Juergen Horn, Dr.med.vet., Ph.D., chief govt officer and co-founder, Invetx makes a speciality of creating novel, protein-based animal well being therapeutics to remodel requirements of care in veterinary drugs. It leverages an built-in biotechnology platform for the invention, improvement, and manufacturing of veterinary monoclonal antibodies, and is growing a various product pipeline addressing continual and extreme ailments in companion animals. Invetx has raised $86 million since 2018, together with traders F-Prime Capital, Novo Holdings, GV, Eight Roads, Anterra Capital, Casdin Capital and funds managed by Tekla Capital Administration, LLC. Strategic funding companions embrace AbCellera, a worldwide know-how firm specializing in antibody discovery positioned in Vancouver, BC, and WuXi Biologics, a worldwide firm with main biologics know-how platforms.
Led by Jesper Nordengaard, chief govt officer, Dechra is a supplier of a veterinary prescription drugs and associated merchandise enterprise. Its experience is within the improvement, manufacture, and gross sales and advertising of merchandise, completely for veterinarians, to assist the sustainable enchancment of animal well being and welfare worldwide.
FinSMEs
19/07/2024
